Patient’s Corner: Living with Chronic Illness Vol. 1

By Dorothy Leon-Glasser

Chronic illness is a disease, condition, or injury that can last years or a lifetime and is typically not curable.  In some cases, it may go into remission, however for most patients it is a lifetime journey.  It can vary in its severity, with some people able to work and live a somewhat active lifestyle; while others are very sick and may even be homebound. For many people there can be long breaks between subsequent episodes of illness. No matter how frequently they experience flares of their disease, patients must continue life on a daily basis until their symptoms can be treated effectively enough to subside again.

Many people with chronic illness have an invisible disease. The severity of their symptoms is not clearly noticeable, which may lead to a lack of understanding and support from doctors, family, friends, coworkers and the public. From many years of caring for chronically ill patients, and being on my own chronic illness journey, it is a fact that ‘no one wants to feel sick’. People with chronic illness are not lazy. The truth is, chronic illness fatigue is more than what a healthy person experiences as ‘being tired’. Once fatigue kicks in, it’s as if the body “hits a wall” and can’t go further. Being chronically ill is like being on an emotional roller coaster. Chronic illness can change the biochemical makeup of the mood control center in the brain, triggering many emotions.

Just before reaching the age of 20, working as a nurse, I became seriously ill. I was unable to eat, dress myself, could barely speak and was completely bed-ridden. I felt like a huge tractor-trailer ran me over and didn’t leave a license number! I was given multiple medications and went through many clinical trials and experimental treatments. After pain-staking tests, doctor examinations, hospital admissions and years of more questions than answers, I was diagnosed. I had a serious chronic illness with a poor prognosis. Through years of much trial and error, self-awareness techniques, counseling, an exceptional health team and much support; I had a new way to live with illness and a new attitude about wellness.

Cory Lewis, Director of Red Moon Project, Sickle Cell Disease shared some challenges of living with sickle cell disease.

“Some obstacles that have been challenging while living here in Georgia is that a lot of the doctors here are still short on knowledge when it comes to sickle cell patients, the culture around sickle cell disease, and the sickle cell types; as they all tend to react and affect the patient differently.”  

Cory affirms that many sickle cell patients are:

  • Forced to look for work that offers benefits to help with medical insurance, however, a lot of these jobs that have benefits require long hours. This can cause stress in the house being away from the ones at home, making sure you don’t lose your job.
  • Constantly have to prove they have an illness, even to health professionals, that people cannot see so they deny disease severity.
  • Manage their illness and our health care system with limited resources. 
  • Face stigma and discrimination from medical team and the public who believe the patient is responsible for being sick.
  • Fight to be acknowledged as individuals each having a unique experience with unique symptoms and side effects from chronic sickle cell disease.

Cory shared his story of his emergency medical experience when he started to have symptoms of renal failure. 

“After moving to Georgia and working, I began to experience fainting and vaso-occlusion to my organs. My kidneys began to fail and my sickle cell was more sensitive than ever before. I was transported to the hospital. A doctor came into the room and automatically assumed I was drug seeking. He looked in my eyes and said ” You don’t have jaundice in your eyes; I don’t see any sickle cell”. He then politely walked out of the room. I was so surprised because I have never been told this, nor have I ever experienced this reaction from any physician. The physician did not leave any treatment orders. Fortunately, a nurse walked in with two cups of water since I was feeling dehydrated.

This was my first time on my own as a young adult tending to my illness. I was shocked to get hit with this stigma and discrimination from the medical staff.  It is not only intimidating to hear a doctor tell you that you don’t have sickle cell but disrespectful when he ignores my knowledge of my body and illness as a sickle cell patient.”

The Ga Bio Patient Advocacy Alliance wants to dispel the myths surrounding chronic illness while telling the story of our advocates who battle their own disease, even as they help others live better lives with theirs. We will be sharing the challenges of having a chronic illness and how we, as patient advocates, can help medical professionals, resources agents and the general public expand their knowledge of what it is like to successfully live with a chronic disease.

In the future, we will continue to hear from other patient advocates who work with people battling chronic illness. We can all make a difference in the lives of those who are ill by gaining a better understanding of what it means to live with a chronic illness. With more understanding of the uniqueness of symptoms and coping skills, we will help make these diseases less “invisible”.        

To learn more about Cory and The Red Moon Project, Inc. click  here  .

Dorothy Leone Glasser headshot
Dorothy Leon Glasser
Executive Director, Advocates for Responsible Care
Co-Chair, Georgia Bio Patient Advocacy Alliance
Cory Lewis
Director, Red Moon Project
By Maria Thacker Goethe July 28, 2025
By: Clary Estes “Small companies are the lifeblood of the industry and a lot of what they do, and what they’re experiencing, greatly affects the industry as a whole,” said Chad Wessel, Director of Industry Analysis at the Biotechnology Innovation Organization (BIO). He spoke with Bio.News in an interview about BIO’s 2025 report, “ The State of Emerging Biotech Companies: Investment, Deal, and Pipeline Trends ,” focused on the biotech industry from the early-stage perspective. As researchers found, the current landscape is challenging, but there are still opportunities. “In the last couple years, we’ve had a little bit of a contraction of the industry. During COVID, we kind of had this sugar rush for the industry,” said Wessel. “A lot of companies were being created. A lot of money was being thrown out there. A lot more companies were being funded. And in the last couple of years, there has been a little bit more of a correction, and we’re seeing funding levels going down to what we’ve seen prior to COVID.” “But when you add on other challenges, like the political landscape and everything, it is leaning towards a very challenging environment for a lot of companies,” he continued. Bearish venture capital “In venture capital, yes, you have a lot of money, but it’s going to fewer companies at higher average amounts,” explained Wessel. “It’s creating this competitive haves and have-nots type marketplace or environment. So it just makes it a lot more competitive and more challenging to raise funds.” Instead of finding new opportunities, venture capitalists are investing more in companies they are already working with. As the BIO report found, the amount of new series A-1 investment rounds into biopharma remained flat between 2023 and 2024, while the number of U.S. companies receiving their first series A-1 tranche went from 102 to 100. This is in comparison to 181 in 2021, reflecting the COVID influx to emerging biotechs. Comparatively, as the BIO report found, the average amount for A-1 transactions in the U.S. saw a remarkable increase of 700% in the last 15 years, with the average amount raised sitting at $60 million in 2024. The rest of the world stayed relatively steady in comparison to the U.S.’s persistent growth. And with the more bearish tendencies of investors, Wessel and team observed an interesting trend. “2024 was the first year that clinical programs actually raised more venture dollars than pre-clinical, which hasn’t happened in a while,” said Wessel. “I think the last time that happened was in 2018. This ties into some of the information that we’ve heard anecdotally, which is that a lot of VC firms are focusing on the companies that they currently have in their portfolio, rather than adding new companies.” Licensing and deals dip It is not too surprising, then, that as investors shore up what they already have in the pipelines, the R&D pipeline and licensing have slowed somewhat. As the BIO report observed, long-term growth in the R&D pipeline continues with an overall growth of 145% since 2010. Yet, the 2024 expansion rate (4.6%) subsided slightly, trailing the 5-year average of 6.7%. “The growth has slowed on new programs, and more of those programs are being licensed with larger companies,” explained Wessel. “There are fewer options for big companies to backfill their pipeline with products because a lot of them are already out.” The data also shows a notable slowing of the R&D typically done by large biopharma companies. “The areas that are not licensed out as much are the ones with some of the higher patient populations and subsequently the ones that are not being run by small companies,” said Wessel. “These are areas like endocrine and cardiovascular diseases, which are areas where there are a lot of things like type 2 diabetes, psoriasis , high blood pressure, etc. Those all have a lot of burden on the healthcare sector or the patient population, and those aren’t really being worked on that much by smaller companies.” Comparatively – and also not surprisingly – oncology has stayed at the top of the clinical pipeline, along with neurology and infectious disease. “Same thing with licensing,” said Wessel. “While there are deals that are still happening, the upfront amount is lower currently than it has been in years past, and most of the value is tied up into milestone payments, which may or may not happen.” This is also being felt when it comes to new companies going public, which has been an oft-discussed challenge in the biotech industry for the last few years. “The IPO market has still been challenging,” Wessel says. “We went from having 40 companies a year going public, down to 15 in 2023, and now we’re back up in 2025, but it’s still down from the pre-COVID era timeframe.” Biopharma layoffs Another notable characteristic of this year’s biopharma landscape has been uptick in layoffs. “Sometimes it’s just the nature of the economy. But the amount that we’ve seen in the last few years is quite a bit higher,” said Wessel. “To counter that, we don’t really have a way of measuring job creation, but we do know it’s happening. We just are unable to put a value on that.” The BIO report found that layoff announcements ticked up to 65 during Q1 of 2025. While two points lower than Q1 of the previous year, this still marks a jump from 2024’s Q2, Q3, and Q4, which saw the number of layoff announcements at 41, 54, and 46, respectively. All in all, Wessel noted, the biotech industry is still in a bit of a holding period when it comes to trying to navigate the coming months. “It’s too early to be able to say much about the coming years for the industry based on these numbers,” he said. “It takes a little time for reality to kind of catch up for multiple reasons. But what I can say is that we do know that companies are reducing their pipelines. We do know that companies are laying off individuals. We do know that companies are having a challenge of raising funds and continue doing their best to try to maintain operations as long as they can until they can get funds.” “We know the challenge is out there, but we’re going to have to kind of wait and see a little bit on the data side of things to understand how everything is going to catch up going forward.” Source: https://bio.news/bioeconomy/bio-2025-state-of-emerging-biotechs-report-market-trends/?mkt_tok=NDkwLUVIWi05OTkAAAGb7m5php-rTOf0a_GTaj5pj7Zl-HlpVM25WtyVvCYudM82a9GKjoazUg9sqU66hlAbhqbEuYvcX3C4EqfBG7Q
By Maria Thacker Goethe July 26, 2025
Pioneer Institute has released updated #340B state fact sheets for 2025
By Georgia Bio Admin July 24, 2025
GLS is proud to announce a new partnership with Apprenti This is a key step toward expanding Registered Apprenticeship programs across Georgia’s thriving life sciences sector. July 24, 2025
MORE POSTS